{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-21-116945","form_type":"8-K","ticker":"MXCT","cik":"0001287098","company_name":"MAXCYTE, INC.","filed_at":"2021-09-17T23:59:59+00:00","discovered_at":"2026-05-14T18:04:17.515417+00:00","generated_at":"2026-06-29T02:53:56.606180+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"MaxCyte Q2 revenue up 38% to $7.1M, net loss widens to $4.4M; guides FY2021 revenue ~$30M","bullets":["Revenue $7.1M (+38% YoY); cell therapy ex-SPL $4.8M (+59%), drug discovery $1.8M (+60%).","Net loss $4.4M vs $3.0M; operating expenses $10.7M (+43%) on higher comp and professional costs.","Signed two new SPL agreements with Celularity and Sana Biotechnology for cell therapy platform.","Completed US IPO on Nasdaq raising $201.8M gross proceeds; cash $73.4M at June 30 pre-IPO.","Preliminary FY2021 revenue guidance of approximately $30M."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-21-116945","json":"https://secwatch.observer/filing/0001104659-21-116945.json","markdown":"https://secwatch.observer/filing/0001104659-21-116945.md","text":"https://secwatch.observer/filing/0001104659-21-116945.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1287098/000110465921116945/0001104659-21-116945-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1287098/000110465921116945/tm2127942d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-29T02:53:56.606180+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}